<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972543</url>
  </required_header>
  <id_info>
    <org_study_id>28861</org_study_id>
    <nct_id>NCT00972543</nct_id>
  </id_info>
  <brief_title>Raptiva in Palm and Sole Psoriasis</brief_title>
  <official_title>A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared
      to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or
      soles scoring Palmo-plantar Pustular Psoriasis Area and Severity Index (PPPASI) ≥5 in
      subjects that are candidates for phototherapy or systemic therapies.

      The rational of the trial is that psoriasis involving palms and/or soles is a painful
      condition associated with fissuring, scaling and in some instances with pustulation. Because
      of its localization, it is a disabling condition that limits dexterity and affects social
      interaction, leading to compromised quality of life; and this confers additional severity to
      that of plaque psoriasis on the body. The therapeutic approach for palm and sole plaque-type
      psoriasis usually begins with topical corticosteroid treatment. If the disease reaches a
      certain extent, the next step involves the addition of systemic treatments. Substances like
      methotrexate, retinoids and cyclosporine have shown to be efficacious, but their long-term
      usage is often limited by toxicity. Biologic treatments for psoriasis avoid this toxicity and
      offer a new therapeutic approach.

      The therapeutic potential of Raptiva® to treat palm and sole psoriasis refractory to systemic
      treatments has been described in numerous case reports and in one placebo-controlled phase IV
      study. However, in all cases, the number of subjects included was low, and in most cases the
      trials were not prospectively designed.

      Since the efficacy of Raptiva® on psoriasis of palms and soles must be determined using the
      validated PPPASI measure, it is necessary for scientific and ethical reasons to include a
      placebo arm during the first 12 weeks. Finally, as the clinical response may sometimes take
      longer than 12 weeks, subjects must be treated and evaluated during an additional 12-week
      open-label extended treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated after the European Medicines Evaluation Agency recommended to suspend
    the marketing authorisation of Raptiva in the European Union
  </why_stopped>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)</measure>
    <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Minimum possible score 0, maximum possible score 72.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Static Physician Global Assessment Hands and Feet (sPGA - H&amp;F)</measure>
    <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20 visits and Early Termination Visit</time_frame>
    <description>Minimum possible score 0, maximum possible score 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Minimum possible score 0, maximum possible score 72.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Static Physician Global Assessment (SPGA)</measure>
    <time_frame>Measured at Screening, Day 0 and Day 7</time_frame>
    <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic Physician's Global Assessment of Change (dPGA)</measure>
    <time_frame>Measured at Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Direct Physical Examination Abnormalities</measure>
    <time_frame>Measured at at screening, Day 0, Week 4, Week 12, and Early Termination visits</time_frame>
    <description>Physical examination included Lymph node palpation, Abdominal palpation, Auscultation of the lung, heart and intestinum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complaint Directed Physical Examinations</measure>
    <time_frame>Measure at (Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits)</time_frame>
    <description>Number of participants undergoing complaint directed physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood Pressure</measure>
    <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Measurements</measure>
    <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Haemoglobin</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Haematocrit</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Red Cell Count</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - White Cell Count</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Platelets</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Neutrophils</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Lymphocytes</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Monocytes</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Eosinophils</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology Laboratory Assessments - Basophils</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Sodium</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Potassium</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Urea</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Creatinine</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Total Bilirubin</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Total Protein</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Calcium</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Aspartate Transaminase</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Alanine Transaminase</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Gamma Glutamyl Transpeptidase</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - Alkaline Phosphatase</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry Laboratory Assessments - C Reactive Protein</measure>
    <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
    <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Serum Human Chorionic Gonadotrophin (hCG) Pregnancy Test</measure>
    <time_frame>Measured at screening (Day -14 to Day -1)</time_frame>
    <description>A serum human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Urinary Human Chorionic Gonadotrophin (hCG) Pregnancy Test</measure>
    <time_frame>Measured at screening (Day -14 to Day -1)</time_frame>
    <description>A urinary human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Raptiva</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Efalizumab (Raptiva)</intervention_name>
    <description>Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.
Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.</description>
    <arm_group_label>Raptiva</arm_group_label>
    <other_name>Raptiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for inclusion into this trial, the subjects must fulfill all of the
        following criteria:

          1. Subjects must have moderate to severe chronic (disease history of at least 6 months
             from diagnosis) plaque psoriasis involving the palms and/or soles (PPPASI =/&gt;5) at
             screening, and must be candidates for phototherapy and systemic therapies.

          2. Subjects must be outpatients.

          3. Subjects must have stable disease at study entry (i.e. no exacerbation of psoriasis
             during the screening period).

          4. Subjects must not have received any systemic psoriasis medication at least 14 days
             prior to the first administration of investigational medicinal product.

          5. Subjects must not have received any topical psoriasis medication at least 14 days
             prior to the first administration of investigational medicinal product (emollients are
             allowed, as well as low potency steroids to the face and/or groin).

          6. Subjects must be at least 18 years old at the time that the informed consent is
             obtained.

          7. Female subjects of childbearing potential must use an adequate method of contraception
             to prevent pregnancy and must agree to continue to practice adequate contraception for
             the duration of their participation in the study (up to the last safety follow up
             visit). For male subjects, it is mandatory to practice birth control during
             participation in the trial, as there are no data on the effect of Raptiva® on
             spermatogenesis. For the purposes of this trial, women of childbearing potential are
             defined as &quot;All female subjects after puberty unless they are post-menopausal for at
             least two years, are surgically sterile or are sexually inactive.&quot; Adequate
             contraception is defined as two barrier methods, or one barrier method with
             spermicide, or an intrauterine device or use of the oral female contraceptive.

          8. Subjects must have discontinued all biological agents at least 3 months prior to the
             first study treatment injection.

          9. Subjects must have discontinued any investigational drug or treatment at least 3
             months prior to study Day 0 and/or as per washout requirements from previous protocol.

         10. Subjects must be willing and able to comply with the protocol requirements for the
             duration of the study.

         11. Subjects must have provided their written informed consent, prior to any study-related
             procedure not part of normal medical care, with the understanding that consent

        Exclusion Criteria:

        To be eligible for inclusion in this trial, the subjects must not meet any of the following
        criteria:

          1. Hypersensitivity to Raptiva®/matching placebo or to any of their excipients.

          2. Current use of any prohibited therapy (systemic or topical treatments for psoriasis,
             such as retinoids; immunosuppressive drugs such as methotrexate, cyclosporine A,
             azathioprine, or mycophenolate mofetil, or any other experimental drug).

          3. Previous or current exposure to Raptiva®.

          4. History of or ongoing alcohol or drug abuse.

          5. History of or ongoing opportunistic infection or other serious infection. This
             includes any infections from the following list: Pneumocystis carinii, cytomegalovirus
             organ infections, Candida albicans (excluding simple localised muco-cutaneous
             infections), mycobacterium infections, Cryptococcus neoformans, Toxoplasma gondii,
             herpes simplex (excluding localised oral or genital muco-cutaneous infection), herpes
             zoster (excluding simple shingle eruption), cryptosporidium, Isospora belli,
             coccidioidomycosis, aspergillosis, histoplasmosis, and nocardiosis. This also includes
             diagnoses requiring more than 2 weeks of therapy, such as endocarditis and
             osteomyelitis treated in the past 6 months. In addition, if the subject is currently
             receiving antibiotics, antivirals, or antifungals for an infection or for suppression
             of or prophylaxis for any diagnosis, the subject will be excluded.

          6. Seropositivity for hepatitis B antigen, hepatitis C antibody, or human
             immunodeficiency virus (HIV). Subjects will undergo testing during screening; any
             subjects who are found to be seropositive for hepatitis B antigen, hepatitis C
             antibody, or HIV will be excluded, and proper diagnosis and further therapy will be
             recommended.

          7. Presence of active tuberculosis.

          8. Presence or history of malignancy including lymphoproliferative disorders.

          9. Pregnancy or breast-feeding.

         10. History of hepatic cirrhosis, regardless of cause or severity.

         11. History or presence of thrombocytopenia, haemolytic anaemia, clinically significant
             anaemia, a white blood cell count &lt;4,000 cells/μL or &gt;14,000 cells/μL, a haematocrit
             (HCT) &lt;30%, a haemoglobin (Hgb) level &lt;11 g/dL, or a platelet count &lt;150,000 cells/μL.

         12. Hepatic enzyme levels =/&gt;3 times the upper limit of normal or serum creatinine level
             =/&gt;2 times the upper limit of normal.

         13. Vaccination with a live or live-attenuated vaccine within the 14 days prior to the
             first dose of investigational medicinal product.

         14. Any medical condition that, in the judgment of the Investigator, would jeopardise the
             subject's safety following exposure to investigational medicinal product (Raptiva® or
             placebo equivalent) or would significantly interfere with the subject's ability to
             comply with the provisions of this protocol.

         15. Other specific forms of psoriasis like guttate, erythrodermic or pustular psoriasis as
             sole or predominant form of psoriasis.

         16. Immunodeficiencies.

         17. Signs and symptoms suggestive of transmissible spongiform encephalopathy or family
             history of such.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Selenko-Gebauer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.A., Geneva</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <results_first_submitted>June 28, 2010</results_first_submitted>
  <results_first_submitted_qc>August 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2010</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe chronic plaque psoriasis</keyword>
  <keyword>palms and/or soles</keyword>
  <keyword>with or without pustules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first subject’s first visit: 29 Sep 2008 Date of last subject’s last visit: 25 May 2009 Subjects were screened at 3 centers in Australia, of which 2 centers enrolled subjects.
It was planned to conduct the trial in centers in Australia and Latin America; however, the trial was terminated before most centers were initiated.</recruitment_details>
      <pre_assignment_details>Screening was performed within 2 weeks prior to starting trial treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raptiva</title>
          <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early study termination by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raptiva</title>
          <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Negative Serum Pregnancy Test</title>
          <description>Participants with negative serum human chorionic gonadotrophin pregnancy test</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not tested (Male or surgically sterile female)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Negative Urinary Pregnancy Test</title>
          <description>Participants with negative urinary human chorionic gonadotrophin pregnancy test</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not tested (Male or surgically sterile female)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)</title>
        <description>Minimum possible score 0, maximum possible score 72.</description>
        <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)</title>
          <description>Minimum possible score 0, maximum possible score 72.</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Static Physician Global Assessment Hands and Feet (sPGA – H&amp;F)</title>
        <description>Minimum possible score 0, maximum possible score 4.</description>
        <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20 visits and Early Termination Visit</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Static Physician Global Assessment Hands and Feet (sPGA – H&amp;F)</title>
          <description>Minimum possible score 0, maximum possible score 4.</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Psoriasis Area and Severity Index (PASI)</title>
        <description>Minimum possible score 0, maximum possible score 72.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI)</title>
          <description>Minimum possible score 0, maximum possible score 72.</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Static Physician Global Assessment (SPGA)</title>
        <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
        <time_frame>Measured at Screening, Day 0 and Day 7</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Static Physician Global Assessment (SPGA)</title>
          <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dynamic Physician's Global Assessment of Change (dPGA)</title>
        <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
        <time_frame>Measured at Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamic Physician's Global Assessment of Change (dPGA)</title>
          <description>The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Direct Physical Examination Abnormalities</title>
        <description>Physical examination included Lymph node palpation, Abdominal palpation, Auscultation of the lung, heart and intestinum</description>
        <time_frame>Measured at at screening, Day 0, Week 4, Week 12, and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Direct Physical Examination Abnormalities</title>
          <description>Physical examination included Lymph node palpation, Abdominal palpation, Auscultation of the lung, heart and intestinum</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complaint Directed Physical Examinations</title>
        <description>Number of participants undergoing complaint directed physical examinations</description>
        <time_frame>Measure at (Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits)</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Complaint Directed Physical Examinations</title>
          <description>Number of participants undergoing complaint directed physical examinations</description>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Blood Pressure</title>
        <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Blood Pressure</title>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Temperature</title>
        <time_frame>Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Temperature</title>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Measurements</title>
        <time_frame>Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <population>Results not analysed due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Measurements</title>
          <population>Results not analysed due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Haemoglobin</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Haemoglobin</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Haematocrit</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Haematocrit</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Red Cell Count</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Red Cell Count</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - White Cell Count</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - White Cell Count</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Platelets</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Platelets</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Neutrophils</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Neutrophils</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Lymphocytes</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Lymphocytes</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Monocytes</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Monocytes</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Eosinophils</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Eosinophils</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology Laboratory Assessments - Basophils</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology Laboratory Assessments - Basophils</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Sodium</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Sodium</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Potassium</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Potassium</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Urea</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Urea</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Creatinine</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Creatinine</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Total Bilirubin</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Total Bilirubin</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Total Protein</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Total Protein</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Calcium</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Calcium</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Aspartate Transaminase</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Aspartate Transaminase</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Alanine Transaminase</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Alanine Transaminase</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Gamma Glutamyl Transpeptidase</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Gamma Glutamyl Transpeptidase</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - Alkaline Phosphatase</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - Alkaline Phosphatase</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry Laboratory Assessments - C Reactive Protein</title>
        <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
        <time_frame>Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Laboratory Assessments - C Reactive Protein</title>
          <description>Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with values reported as adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Serum Human Chorionic Gonadotrophin (hCG) Pregnancy Test</title>
        <description>A serum human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
        <time_frame>Measured at screening (Day -14 to Day -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Serum Human Chorionic Gonadotrophin (hCG) Pregnancy Test</title>
          <description>A serum human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not tested (Male or surgically sterile female)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Urinary Human Chorionic Gonadotrophin (hCG) Pregnancy Test</title>
        <description>A urinary human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
        <time_frame>Measured at screening (Day -14 to Day -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raptiva</title>
            <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Urinary Human Chorionic Gonadotrophin (hCG) Pregnancy Test</title>
          <description>A urinary human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not tested (Male or surgically sterile female)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raptiva</title>
          <description>Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Left eye redness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized body ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Swelling of left heel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Folliculitis of groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Secondary infection, both feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infected right foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cellulitis right leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral arm aches (nonspecific)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intertrigo of groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Contact dermatitis, both feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Maculopapular rash on body (id reaction)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Widespread eczematous rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Telogen effluvium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eczematous rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Responsible</name_or_title>
      <organization>Merck Serono S.A., a division of Merck KGaA</organization>
      <phone>+49-6151-75-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

